Compound Screening TRIZ Cases

Photoreactive lipid probes harvest binding complexes via covalent crosslinking, resolving low identification efficiency in conventional assays.

Administering a CCNY inhibitor increases GluA1 receptor surface delivery to improve learning and memory while reducing CCNY protein levels.

Segmented detection antibodies bridge enzymatic cleavage and signal generation, resolving the trade-off between measurement precision and assay complexity.

Segmented TASQ compounds resolve intramolecular affinity loss by using flexible linkers between binding cores and biotin tags.

Isolating the BCL10 protein complex reveals apoptosis mechanisms and NF-kB activation pathways, enabling diagnosis of cancer and inflammatory diseases.

Computational variant capture maps estimate protein properties using spatial covariance and 3D distance data.

GCaMP variants replace synthetic dyes to enable chronic in vivo measurements without tissue damage while maintaining precise calcium detection.

Selective SCF-Skp2 inhibitors increase p27 levels and induce cell cycle arrest without causing peripheral neuropathy.

Segmented fluorescent RBM20 condensate assays identify modulating compounds to address unclear disease mechanisms in dilated cardiomyopathy.

Integrates multiple transcriptional regulatory regions into a single construct to detect membrane protein activation with high sensitivity.

CRISPR deletion of CTCF binding sites at promoter regions disrupts enhancer contacts, reducing MYC expression and tumor proliferation.

Extracting detection targets to the XPR1 cell surface transporter eliminates complex permeabilization steps while maintaining accurate senescence assessment.

A bifunctional PROTAC compound links a DNA polymerase ligand to an E3 ubiquitin ligase ligand via a linker.

Reverse osmosis separates ethanol from agave spirits to preserve MAO inhibition activity lost during conventional distillation.

Targeting XBP-1 with nucleic acids resolves the trade-off between treating dyslipidemia and preserving protein secretory function.

Targeting iRhom1 and iRhom2 regulators overcomes complex ligand release constraints that limit conventional EGFR inhibitors.

Class 1 olfactory receptors bind sweat carboxylic acids to enable targeted deodorant blocker development.

A diagnostic composition measures specific polypeptide expression levels in blood samples using magnetic bead enrichment for rapid analysis.

Cyclic-GMP-AMP synthase inhibitors target aberrant cytosolic DNA sensing to treat autoimmune diseases with fewer side effects.

Fluorescently labeled circular DNA detects topoisomerase activity changes to replace labor-intensive gel electrophoresis methods.

A cAngptl4 antibody binds specifically to the C-terminal fragment of angiopoietin-related protein 4 to facilitate lung tissue repair.

Exogenous regulatory factors in cancer cells enable therapeutic drug screening without identifying target proteins, reducing time spent on gene identification.

HGF-based agents promote lymphatic endothelial cell growth to induce lymphangiogenesis, addressing the edema risks associated with VEGF therapies.

USP5 inhibitors increase Cav3.2 ubiquitination, reducing channel activity and alleviating neuropathic pain.

A chimeric umami taste receptor expands the detection signal window in eukaryotic cells.

Junction plakoglobin expression levels in blood samples enable sensitive ovarian cancer detection through antibody-based assays.

Linoleic acid complexes bind to coronavirus spike protein pockets, inhibiting receptor attachment and reducing viral infectivity.

LRP4 autoantibody detection resolves seronegative myasthenia gravis diagnostic gaps by identifying specific antibody-antigen complexes.

Low-dose tocilizumab treats cytokine release syndrome while conserving limited therapeutic supplies.

Photopolymerizable hydrogels enable directional locomotion while resolving the trade-off between structural strength and tissue-like elasticity.

A gravity flow micro-physiological article divides fluid using a liquid divider to determine physiological responses.

A pharmaceutical composition containing TGase2 inhibitors targets transglutaminase 2 activity to prevent vascular leakage.

Segmenting genome-wide methylomic profiling into curated CpG markers resolves the contradiction between measurement precision and system complexity.

Glycosylated S1F polypeptides immobilized on microtiter plates increase detection sensitivity for SARS-CoV-2 spike protein inhibitors.

Targeting peptides and antibodies recognize distinct Alzheimer's disease brain stages to enable precise molecular diagnostics.

Polyspecific reagents detect off-target binding in polypeptide libraries, filtering poor candidates early to reduce downstream resource expenditure.

Hydrostatic pressure differentials drive fluid flow through microchannels, resolving throughput and precision trade-offs in kinase inhibitor screening.

Transitioning CRFK cells to suspension culture eliminates serum contamination risks while maintaining viral antigen sensitivity and reducing production costs.

A multiplex microfluidic device segments binding channels to isolate nucleic acid aptamers for multiple targets simultaneously.

Multivariate classification algorithms assign phenotypic signatures to cells in liquid biological samples for diagnostic applications.

A theranostics platform combines optical imaging with automated analysis to identify drug candidates normalizing rare disease cell phenotypes.

A competitive ligand method ranks target affinity through filtration and chromatography.

A non-invasive diagnostic method uses serum metabolic profiles to identify specific biomarkers.

Purifying viral enzymes from patient plasma enables direct phenotypic drug susceptibility assessment.

Tat-associated protein engineering screens antibody domains via bacterial translocation.

Measuring TDP-43 and p65 NF-kB protein interaction levels enables precise biochemical detection of amyotrophic lateral sclerosis pathology.

Peptides bind the Pin1 active site to block catalysis, avoiding genetic depletion complexity and off-target effects.

Engineered non-human mast cell progenitors express human IgE receptors to standardize diagnostic testing.